Backhouse J L, Gidding H F, MacIntyre C R, McIntyre P B, Gilbert G L
Centre for Infectious Diseases and Microbiology-Public Health and Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales 2145, Australia.
Vaccine. 2007 Jan 26;25(7):1310-5. doi: 10.1016/j.vaccine.2006.09.087. Epub 2006 Oct 10.
Neisseria meningitidis serogroup C (NMC) conjugate vaccine was introduced, in Australia, in 2003. Our aims were to determine pre-immunisation IgG NMC seroprevalence and evaluate an enzyme-linked immunosorbent assay (ELISA), previously validated against the serum bactericidal assay (SBA). 2409 sera, collected in 2002, from subjects aged 2-34 years, were tested. The geometric mean concentration (GMC) of NMC anticapsular IgG was 0.38 U/mL in subjects under 19 years and it increased to 0.67 U/mL for those aged 30-34 years. Variation in GMC correlated with reported NMC disease incidence and was higher in males than females (0.52 U/mL versus 0.41 U/mL; p=0.005). The ELISA appears suitable for serosurveillance but the IgG level that correlates with protection needs further investigation. Serosurveys will be repeated to monitor the impact of vaccination.
2003年，澳大利亚引入了C群脑膜炎奈瑟菌（NMC）结合疫苗。我们的目的是确定免疫前IgG NMC血清阳性率，并评估一种酶联免疫吸附测定（ELISA），该测定先前已针对血清杀菌试验（SBA）进行了验证。对2002年收集的2409份年龄在2至34岁之间的受试者血清进行了检测。19岁以下受试者中NMC抗荚膜IgG的几何平均浓度（GMC）为0.38 U/mL，30至34岁受试者的该浓度升至0.67 U/mL。GMC的变化与报告的NMC疾病发病率相关，且男性高于女性（0.52 U/mL对0.41 U/mL；p=0.005）。ELISA似乎适用于血清学监测，但与保护相关的IgG水平需要进一步研究。将重复进行血清学调查以监测疫苗接种的影响。
